Notice of Correction for Announcement of Requirements and Registration for “Antimicrobial Resistance Rapid, Point-of-Need Diagnostic Test” Challenge, 68020-68021 [2016-23854]

Download as PDF sradovich on DSK3GMQ082PROD with NOTICES 68020 Federal Register / Vol. 81, No. 191 / Monday, October 3, 2016 / Notices 7W264, Rockville, MD 20892–9750, 240–276–6384, gravesr@mail.nih.gov. Name of Committee: National Cancer Institute Special Emphasis Panel; NCI Provocative Questions—PQ4. Date: November 3, 2016. Time: 12:00 p.m. to 3:00 p.m. Agenda: To review and evaluate grant applications. Place: National Cancer Institute, Shady Grove, 9609 Medical Center Drive, Room 7W032/034, Rockville, MD 20850, (Telephone Conference Call). Contact Person: Zhiqiang Zou, MD, Ph.D., Scientific Review Officer, Special Review Branch, Division of Extramural Activities, National Cancer Institute, 9609 Medical Center Drive, Room 7W242, Rockville, MD 20892–9750, 240–276–6372, zouzhiq@mail.nih.gov. Name of Committee: National Cancer Institute Special Emphasis Panel; Fundamental Mechanisms of Affective and Decisional Process in Cancer Control. Date: November 4, 2016. Time: 11:00 a.m. to 4:00 p.m. Agenda: To review and evaluate grant applications. Place: National Cancer Institute, Shady Grove, 9609 Medical Center Drive, Room 2W910, Rockville, MD 20850, (Telephone Conference Call). Contact Person: Thomas A. Winters, Ph.D., Scientific Review Officer, Special Review Branch, Division of Extramural Activities, National Cancer Institute, 9609 Medical Center Drive, Room 7W112, Rockville, MD 20892–9750, 240–276–6386, twinters@mail.nih.gov. Name of Committee: National Cancer Institute Special Emphasis Panel; NCI Provocative Questions—PQ6. Date: November 4, 2016. Time: 12:00 p.m. to 4:00 p.m. Agenda: To review and evaluate grant applications. Place: National Cancer Institute, Shady Grove, 9609 Medical Center Drive, Room 6W034, Rockville, MD 20850, (Telephone Conference Call). Contact Person: Zhiqiang Zou, MD, Ph.D., Scientific Review Officer, Special Review Branch, Division of Extramural Activities, National Cancer Institute, 9609 Medical Center Drive, Room 7W242, Rockville, MD 20892–9750, 240–276–6372, zouzhiq@mail.nih.gov. Name of Committee: National Cancer Institute Special Emphasis Panel; NCI Provocative Questions—PQ8. Date: November 10, 2016. Time: 12:00 p.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: National Cancer Institute, Shady Grove, 9609 Medical Center Drive, Room 7W032/034, Rockville, MD 20850, (Telephone Conference Call). VerDate Sep<11>2014 17:56 Sep 30, 2016 Jkt 241001 Contact Person: Yisong Wang, Ph.D., Scientific Review Officer, Special Review Branch, Division of Extramural Activities, National Cancer Institute, 9609 Medical Center Drive, Room 7W240, Rockville, MD 20892–9750, 240–276–7157, yisong.wang@nih.gov. Name of Committee: National Cancer Institute Special Emphasis Panel; Provocative Questions in Cancer with an Underlying HIV Infection. Date: November 16, 2016. Time: 11:00 a.m. to 4:00 p.m. Agenda: To review and evaluate grant applications. Place: National Cancer Institute, Shady Grove, 9609 Medical Center Drive, Room 4E030, Rockville, MD 20850, (Telephone Conference Call). Contact Person: Clifford W. Schweinfest, Ph.D., Scientific Review Officer, Special Review Branch, Division of Extramural Activities, National Cancer Institute, 9609 Medical Center Drive, Room 7W108, Rockville, MD 20892–9750, 240–276–6343, schweinfestcw@mail.nih.gov. Name of Committee: National Institute on Aging Special Emphasis Panel; Multi–Omics in Osteoporosis. Date: October 25, 2016. Time: 1:00 p.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institute on Aging, Gateway Building, 2W200, 7201 Wisconsin Avenue, Bethesda, MD 20892, (Telephone Conference Call). Contact Person: Nijaguna Prasad, MS, Ph.D., Scientific Review Officer, Scientific Review Branch, National Institute of Aging, National Institutes of Health, Bethesda, MD 20892, 301–496–9667, nijaguna.prasad@ nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.866, Aging Research, National Institutes of Health, HHS) (Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS) DEPARTMENT OF HEALTH AND HUMAN SERVICES Dated: September 27, 2016. Melanie J. Gray, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2016–23734 Filed 9–30–16; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute on Aging; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. PO 00000 Frm 00065 Fmt 4703 Sfmt 4703 Dated: September 27, 2016. Melanie J. Gray, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2016–23735 Filed 9–30–16; 8:45 am] BILLING CODE 4140–01–P National Institutes of Health Notice of Correction for Announcement of Requirements and Registration for ‘‘Antimicrobial Resistance Rapid, Point-of-Need Diagnostic Test’’ Challenge The National Institutes of Health (NIH) is correcting a notice previously published in the Federal Register on September 8, 2016 (81 FR 62150), titled ‘‘Announcement of Requirements and Registration for ‘Antimicrobial Resistance Rapid, Point-of-Need Diagnostic Test’ Challenge.’’ The notice announced the Antimicrobial Resistance Rapid, Point-of-Need challenge competition that may result in the awarding of $20 million dollars for the successful development of new, innovative, accurate, and cost-effective in vitro diagnostic tests that would rapidly inform clinical treatment decisions and be of significant clinical and public health utility to combat the development and spread of antibiotic resistant bacteria and improve antibiotic stewardship. The NIH is correcting and clarifying several components of the Challenge competition including: (1) The letter of intent must be submitted by December 23, 2016, for all ‘‘Solvers’’ planning to submit for the Step 1 (Theoretical) stage of the competition. The September 8, 2016 announcement incorrectly stated that the letter of intent prior to Step 1 was E:\FR\FM\03OCN1.SGM 03OCN1 sradovich on DSK3GMQ082PROD with NOTICES Federal Register / Vol. 81, No. 191 / Monday, October 3, 2016 / Notices required but a specific due date was not stated. (2) Any Appendix submitted for Step 1 of the Challenge competition must be limited to 5 pages or less in length. If a longer Appendix is submitted, only the first 5 pages will be considered by the Technical Evaluation Panel and the Judging Panel. The September 8, 2016, announcement incorrectly stated that there was no page length for the Appendix material. (3) Submissions for Step 1 of the Challenge competition received after the deadline of January 9, 2017, at 11:59 p.m. ET will be disqualified and not evaluated by the Technical Evaluation Panel or Judging Panel. (4) Solvers may submit corrections or additional materials in support of their Step 1 submissions so long as the NIH receives the materials by the deadline of January 9, 2017, at 11:59 p.m. ET. Corrections or additional materials for Step 1 will not be accepted or evaluated by the Technical Evaluation Panel or Judging Panel if they are received after January 9, 2017 at 11:59 p.m. ET. (5) The NIH will perform an initial review of all submissions to ensure they are complete and within the scope of the Challenge competition. Submissions that are incomplete will be administratively disqualified and will not be evaluated by the Technical Evaluation Panel or the Judging Panel. (6) The NIH and Assistant Secretary for Preparedness and Response/ Biomedical Advanced Research and Development Authority may determine that based on the number of submissions received for Step 1 that less competitive submissions will not be discussed by the Technical Evaluation Panel during the Panel’s meeting. (7) The ‘‘Solver’’ needs to address the NIH Human Subjects Protections and Inclusion of Women, Children, and Minorities policies in their submissions for Step 1 of this competition. (8) Members of the Technical Evaluation Panel are not eligible to participate in or contribute to any proposal for Step 2 and Step 3 of the Challenge competition. (9) Any Solver is eligible for Step 2 of this Challenge competition. For example, if a Step 1 ‘‘Solver’’ is not identified as a semifinalist, he/she may still submit for Step 2 of this competition and those who did not submit a Step 1 proposal may still submit a proposal for Step 2. (10) All submissions for Step 1, 2, and 3 must be in English. For further information about the Antimicrobial Resistance Diagnostic Challenge competition, please contact Robert W. Eisinger, Ph.D., NIH, 301– VerDate Sep<11>2014 17:56 Sep 30, 2016 Jkt 241001 68021 496–2229 or by email Robert.eisinger@nih.gov. DEPARTMENT OF HEALTH AND HUMAN SERVICES Dated: September 27, 2016. Lawrence A. Tabak, Deputy Director, National Institutes of Health. Substance Abuse and Mental Health Services Administration [FR Doc. 2016–23854 Filed 9–30–16; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel; NIAID Clinical Trial Planning Grant (R34) and NIAID Investigator Initiated Program Project Applications (P01). Date: October 28, 2016. Time: 8:00 a.m. to 3:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 5601 Fishers Lane, Rockville, MD 20892, (Telephone Conference Call). Contact Person: Zhuqing (Charlie) Li, Ph.D., Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, Room # 3G41B, National Institutes of Health/NIAID, 5601 Fishers Lane, MSC9823 Bethesda, MD 20892–9823, (240) 669–5068, zhuqing.li@nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS) Dated: September 27, 2016. Natasha M. Copeland, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2016–23736 Filed 9–30–16; 8:45 am] BILLING CODE 4140–01–P PO 00000 Frm 00066 Fmt 4703 Sfmt 4703 Current List of HHS-Certified Laboratories and Instrumented Initial Testing Facilities Which Meet Minimum Standards To Engage in Urine Drug Testing for Federal Agencies Substance Abuse and Mental Health Services Administration, HHS ACTION: Notice. AGENCY: The Department of Health and Human Services (HHS) notifies federal agencies of the laboratories and Instrumented Initial Testing Facilities (IITF) currently certified to meet the standards of the Mandatory Guidelines for Federal Workplace Drug Testing Programs (Mandatory Guidelines). The Mandatory Guidelines were first published in the Federal Register on April 11, 1988 (53 FR 11970), and subsequently revised in the Federal Register on June 9, 1994 (59 FR 29908); September 30, 1997 (62 FR 51118); April 13, 2004 (69 FR 19644); November 25, 2008 (73 FR 71858); December 10, 2008 (73 FR 75122); and on April 30, 2010 (75 FR 22809). A notice listing all currently HHScertified laboratories and IITFs is published in the Federal Register during the first week of each month. If any laboratory or IITF certification is suspended or revoked, the laboratory or IITF will be omitted from subsequent lists until such time as it is restored to full certification under the Mandatory Guidelines. If any laboratory or IITF has withdrawn from the HHS National Laboratory Certification Program (NLCP) during the past month, it will be listed at the end and will be omitted from the monthly listing thereafter. This notice is also available on the Internet at http://www.samhsa.gov/ workplace. SUMMARY: FOR FURTHER INFORMATION CONTACT: Giselle Hersh, Division of Workplace Programs, SAMHSA/CSAP, 5600 Fishers Lane, Room 16N03A, Rockville, Maryland 20857; 240–276–2600 (voice). SUPPLEMENTARY INFORMATION: The Mandatory Guidelines were initially developed in accordance with Executive Order 12564 and section 503 of Public Law 100–71. The ‘‘Mandatory Guidelines for Federal Workplace Drug Testing Programs,’’ as amended in the revisions listed above, requires strict standards that laboratories and IITFs must meet in order to conduct drug and E:\FR\FM\03OCN1.SGM 03OCN1

Agencies

[Federal Register Volume 81, Number 191 (Monday, October 3, 2016)]
[Notices]
[Pages 68020-68021]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-23854]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Notice of Correction for Announcement of Requirements and 
Registration for ``Antimicrobial Resistance Rapid, Point-of-Need 
Diagnostic Test'' Challenge

    The National Institutes of Health (NIH) is correcting a notice 
previously published in the Federal Register on September 8, 2016 (81 
FR 62150), titled ``Announcement of Requirements and Registration for 
`Antimicrobial Resistance Rapid, Point-of-Need Diagnostic Test' 
Challenge.'' The notice announced the Antimicrobial Resistance Rapid, 
Point-of-Need challenge competition that may result in the awarding of 
$20 million dollars for the successful development of new, innovative, 
accurate, and cost-effective in vitro diagnostic tests that would 
rapidly inform clinical treatment decisions and be of significant 
clinical and public health utility to combat the development and spread 
of antibiotic resistant bacteria and improve antibiotic stewardship.
    The NIH is correcting and clarifying several components of the 
Challenge competition including:
    (1) The letter of intent must be submitted by December 23, 2016, 
for all ``Solvers'' planning to submit for the Step 1 (Theoretical) 
stage of the competition. The September 8, 2016 announcement 
incorrectly stated that the letter of intent prior to Step 1 was

[[Page 68021]]

required but a specific due date was not stated.
    (2) Any Appendix submitted for Step 1 of the Challenge competition 
must be limited to 5 pages or less in length. If a longer Appendix is 
submitted, only the first 5 pages will be considered by the Technical 
Evaluation Panel and the Judging Panel. The September 8, 2016, 
announcement incorrectly stated that there was no page length for the 
Appendix material.
    (3) Submissions for Step 1 of the Challenge competition received 
after the deadline of January 9, 2017, at 11:59 p.m. ET will be 
disqualified and not evaluated by the Technical Evaluation Panel or 
Judging Panel.
    (4) Solvers may submit corrections or additional materials in 
support of their Step 1 submissions so long as the NIH receives the 
materials by the deadline of January 9, 2017, at 11:59 p.m. ET. 
Corrections or additional materials for Step 1 will not be accepted or 
evaluated by the Technical Evaluation Panel or Judging Panel if they 
are received after January 9, 2017 at 11:59 p.m. ET.
    (5) The NIH will perform an initial review of all submissions to 
ensure they are complete and within the scope of the Challenge 
competition. Submissions that are incomplete will be administratively 
disqualified and will not be evaluated by the Technical Evaluation 
Panel or the Judging Panel.
    (6) The NIH and Assistant Secretary for Preparedness and Response/
Biomedical Advanced Research and Development Authority may determine 
that based on the number of submissions received for Step 1 that less 
competitive submissions will not be discussed by the Technical 
Evaluation Panel during the Panel's meeting.
    (7) The ``Solver'' needs to address the NIH Human Subjects 
Protections and Inclusion of Women, Children, and Minorities policies 
in their submissions for Step 1 of this competition.
    (8) Members of the Technical Evaluation Panel are not eligible to 
participate in or contribute to any proposal for Step 2 and Step 3 of 
the Challenge competition.
    (9) Any Solver is eligible for Step 2 of this Challenge 
competition. For example, if a Step 1 ``Solver'' is not identified as a 
semifinalist, he/she may still submit for Step 2 of this competition 
and those who did not submit a Step 1 proposal may still submit a 
proposal for Step 2.
    (10) All submissions for Step 1, 2, and 3 must be in English.
    For further information about the Antimicrobial Resistance 
Diagnostic Challenge competition, please contact Robert W. Eisinger, 
Ph.D., NIH, 301-496-2229 or by email Robert.eisinger@nih.gov.

    Dated: September 27, 2016.
Lawrence A. Tabak,
Deputy Director, National Institutes of Health.
[FR Doc. 2016-23854 Filed 9-30-16; 8:45 am]
 BILLING CODE 4140-01-P